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Risk Assessment: Good Science for
Good Decisions
The recent flurry ofactivity and intense controversy associated with
health risk assessment and its use in regulatory decisions is generated
by a number of forces including concerns of industry that costs of
complying with environmental regulations are excessive; concerns of
environmentalists that risk assessment practices and policies do not
adequately protect human and environmental health; the public's
lack of confidence in regulatory decision-making; and increasing
awareness that the scientific foundation for many risk assessments is
weak.
In an attempt to shed some light on these issues, a large portion
of the Environews section of this issue of Environmental Health
Perspectives is devoted to the topic ofrisk assessment. The Focus arti-
cles evaluate the utility of animal models in risk assessment and
describe a report on federal programs in health risk assessment
research prepared by the Office of Technology Assessment at the
request of the U.S. Congress. The Spheres of Influence section
addresses the potential impact and reactions to current legislative ini-
tiatives on risk assessment.
Other risk assessment activities not covered in this issue include
an attempt by the National Research Council to achieve consensus
on risk assessment issues, most recently regarding the issue ofthe use
ofthe maximum tolerated dose (MTD) in toxicity testing (see EHP
101:19), an evaluation of regulatory policies by the Carnegie
Commission, and attempts by industrial groups such as the Chemical
Manufacturing Association and the Chlorine Institute to identify
possible areas of overregulation that might adversely affect their
industries.
The debate over risk assessment is politically and emotionally
charged, creating an adversarial atmosphere heightened by the extra-
ordinary sums of money at stake in current toxic tort litigations.
Current lawsuits over dioxin alone involve several hundreds of bil-
lions of dollars; the bill for just one class action lawsuit against a
member ofthe American Paper Institute is $100 billion. The poten-
tial litigation price tag rivals the dollar amounts involved in the con-
troversial budget deficit reduction package; no wonder the debate is
often hostile and self-serving. The economic impact of risk assess-
ments is further underscored by the cost ofcompliancewith regulato-
ry mandates; estimates for American industries range from $150 bil-
lion to $400 billion a year. Health care costs for environmentally
induced diseases are difficult to estimate because ofdisagreement over
the magnitude ofadverse health effects resulting from low-level expo-
sure to many chemicals and the fact that little or no toxicological
information is available for the majority ofchemicals released into the
environment. Despite the uncertainty in estimates, health care costs
related to chemical exposure surely involves many billions ofdollars.
Taken together, costs ofhealth care, litigation, and regulatory com-
pliance total nearly a trillion dollars, many ofwhich, depending on
the point ofview, may be unnecessary and/or preventable.
Resolution ofthe controversy, development ofeffective preven-
tion strategies, and rational priority setting can only be achieved by
strengthening the database used to make regulatory decisions. A
recent estimate of federal expenditures for health risk-assessment-
related research is $600 million a year; however, this figure is prob-
ably greater than the actual dollars spent. Although this seems to
be a huge sum, it is negligible in comparison to the costs of the
consequences of regulatory decisions. Regulatory agencies need
better data and better methods to assess risks. This does not mean
that we should redirect resources from basic to applied research, for
basic research provides the fountain ofnew knowledge that is essen-
tial for the development of meaningful applied research. To be
most effective, basic and applied research must move forward
together. It will likely be economically impossible to completely
test for toxic effects for all the chemicals released into the environ-
ment. Therefore, we need to develop ways ofmore accurately pre-
dicting risk based on limited but critical pieces of scientific infor-
mation. An approach that combines appropriate epidemiological,
toxicological, in vitro, and mechanistic data with estimates from
"predictive toxicology" is clearly needed.
Risk assessments for a given exposure often vary tremendously
depending on the assumptions made to compensate for a lack of
adequate data. This uncertainty could be potentially lessened in a
number of ways with better information on how environmental
agents interact with and perturb biological systems. First, the most
appropriate animal or in vitro models for estimating human risks
could be selected, based on comparative data of mechanisms and
dosimetry. Second, dose-response relationships could be more
accurately determined by the use ofbiomarkers by quantification of
critical molecular events in the low-dose region that precede and
predict toxic responses. Third, the magnitude ofhuman exposure
to selected chemicals could be determined by the appropriate use of
sensitive and specific biomarkers. Finally, methods could be devised
to identify individuals or populations who might be at special risk
to environmentally mediated health effects. To be most effective,
scientists from a variety ofdisciplines and regulatory officials must
work together, putting aside narrow perspectives and preconceived
notions about the scientific worthiness of different disciplines.
Communication is essential, not only among scientists and regula-
tors, but also between scientists and the public whose health and
well-being is affected by regulatory decisions.
The point to remember is that the purpose ofrisk assessment is
to prevent adverse health effects from chemical exposures.
Accuracy ofrisk estimates can only be improved by better scientific
data and better methods for incorporating such data into the risk
assessment process. The enormous costs, both in dollars and
human health, associated with risk assessment decisions represent
compelling justification for the development ofa national policy to
strengthen the scientific foundations on which risk assessments are
based.
GeorgeW. Lucier
Environmental Health Perspectives 366